ZILBRYSQ FAQs

ZILBRYSQ is a prescribed medicine used to treat adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if ZILBRYSQ is safe and effective for the treatment of gMG in children.

ZILBRYSQ is a medicine that affects part of your immune system. ZILBRYSQ may lower the ability of your immune system to fight infections.

• ZILBRYSQ increases your chance of getting serious meningococcal infections caused by Neisseria meningitidis bacteria. Meningococcal infections may quickly become life-threatening or cause death if not recognized and treated early.
  • You must complete or update your meningococcal vaccine(s) at least 2 weeks before your first dose of ZILBRYSQ.
  • If you have not completed your meningococcal vaccines and ZILBRYSQ must be started right away, you should receive the required vaccine(s) as soon as possible.
  • If you have not been vaccinated and ZILBRYSQ must be started right away, you should also receive antibiotics to take for as long as your healthcare provider tells you.
  • If you had a meningococcal vaccine in the past, you might need additional vaccines before starting ZILBRYSQ. Your healthcare provider will decide if you need additional meningococcal vaccines.
  • Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection:
    • fever
    • fever with high heart rate
    • headache and fever
    • confusion
    • muscle aches with flu-like symptoms
    • fever and a rash
    • headache with nausea or vomiting
    • headache with a stiff neck or stiff back
    • eyes sensitive to light

Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection. Carry it with you at all times during treatment and for 2 months after your last ZILBRYSQ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of ZILBRYSQ. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.

ZILBRYSQ is only available through a program called the ZILBRYSQ Risk Evaluation and Mitigation Strategy (REMS). Before you can receive ZILBRYSQ, your healthcare provider must:

• enroll in the ZILBRYSQ REMS program.
• counsel you about the risk of meningococcal infections.
• give you the Patient Guide, including information about the signs and symptoms of meningococcal infection.
• give you a Patient Safety Card about your risk of meningococcal infection, as discussed above.
• make sure that you are vaccinated against serious infections caused by meningococcal bacteria and that you receive antibiotics if you need to start ZILBRYSQ right away and you are not up to date on your vaccines.

ZILBRYSQ may also increase the risk of other types of serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. 

• Certain people may be at risk of serious infections with gonorrhea. Talk to your healthcare provider about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and about regular testing.

Call your healthcare provider right away if you have new signs or symptoms of infection.

If you have been wanting an at-home, self-administered treatment for generalized myasthenia gravis, then you may want to consider ZILBRYSQ.

Ask your doctor about ZILBRYSQ. Download our Doctor Discussion Guide to help you get the conversation started.

Do not use ZILBRYSQ if you have a serious meningococcal infection when you are starting ZILBRYSQ treatment.

ZILBRYSQ targets a source of gMG symptoms. ZILBRYSQ works by targeting and blocking an activated complement protein in the immune system that is a key cause of gMG symptoms. By blocking a critical complement protein, ZILBRYSQ may help to prevent the muscle cell damage that interrupts signals between nerves and muscles.

The exact mechanism by which ZILBRYSQ works in gMG is unknown.

ZILBRYSQ is a self-administered treatment for adults with anti-AChR antibody-positive gMG. In a clinical trial, people taking ZILBRYSQ experienced significant improvements in activities of daily living as measured by the MG-ADL Scale at 12 weeks. Individual results may vary; not all people taking ZILBRYSQ will experience improvements. See the clinical trial results.

In a clinical trial, people taking ZILBRYSQ experienced significant improvements in activities of daily living as measured by the MG-ADL Scale at 12 weeks. Individual results may vary; not all people taking ZILBRYSQ will experience improvements. See the clinical trial results.

See the detailed Instructions for Use that comes with your ZILBRYSQ for information on how to prepare and inject a dose of ZILBRYSQ, and how to properly throw away (dispose of) used ZILBRYSQ prefilled syringes.

• ZILBRYSQ is given as an injection under the skin (for subcutaneous use) in a prefilled syringe. Use ZILBRYSQ exactly as prescribed by your healthcare provider.
• After proper training on how to prepare and inject your ZILBRYSQ syringe, you or your caregiver will inject ZILBRYSQ daily. Your healthcare provider will decide the total daily dose depending on your body weight.
• Each prefilled syringe is for single-use only. Discard the prefilled syringe after each use. Do not reuse.
• Your daily dose of ZILBRYSQ should be injected at approximately the same time each day.

If you miss your ZILBRYSQ dose, inject a dose as soon as possible. Then, inject your next dose at your regular scheduled time. Do not inject more than 1 dose each day. Call your healthcare provider if you are not sure what to do.

ZILBRYSQ may cause serious side effects, including:

• See “What is the most important information I should know about ZILBRYSQ?”
• Inflammation of the pancreas (pancreatitis) and other pancreatic problems. Pancreatitis and pancreatic cysts have happened in people who use ZILBRYSQ. Your healthcare provider will do blood tests to check your pancreas before you start treatment with ZILBRYSQ.
  • Call your healthcare provider right away if you have pain in your stomach area (abdomen) that will not go away. Your healthcare provider will tell you if you should stop using ZILBRYSQ. The pain may be severe or felt going from your abdomen to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis.

The most common side effects of ZILBRYSQ include:

• injection site reactions.
• upper respiratory tract infections.
• diarrhea.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ZILBRYSQ. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at www.fda.gov/medwatch or 1-800-FDA-1088. You may also report side effects to UCB, Inc. by calling 1-844-599-CARE [2273].

• ZILBRYSQ prefilled syringes may be stored in the refrigerator between 36°F to 46°F (2°C to 8°C) until the expiration date on the carton. Do not freeze ZILBRYSQ. Keep the prefilled syringes in the original carton until ready for use to protect from light.
• ZILBRYSQ prefilled syringes may be stored at room temperature up to 86°F (30°C) in the original carton to protect them from light for a single period of up to 3 months. Write the date you removed the prefilled syringes from the refrigerator in the space provided on the carton. After ZILBRYSQ prefilled syringes have been stored at room temperature, do not place them back in the refrigerator and throw them away if not used within the 3-month period or if the expiration date has passed, whichever occurs first.
• Throw away any unused portion.

Keep ZILBRYSQ prefilled syringes and all medicines out of the reach of children.

For more information about storing and taking ZILBRYSQ, visit the How to Use ZILBRYSQ page.

In clinical studies, patients stayed on their current treatment while receiving subcutaneous injections of ZILBRYSQ. Talk to your healthcare team about the medications you are taking as part of your treatment plan for gMG.

Tell your healthcare provider about all of your medical conditions, including if you:

• have an infection or fever.
• are pregnant or plan to become pregnant. It is not known if ZILBRYSQ will harm your unborn baby.
  • Pregnancy Registry: There is a pregnancy registry for women who use ZILBRYSQ during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become pregnant while taking ZILBRYSQ, you or your healthcare provider can contact UCBCares^® at 1-844-599-CARE (2273) or email ucbcares@ucb.com to enroll or get more information about the registry.
• are breastfeeding or plan to breastfeed. It is not known if ZILBRYSQ passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use ZILBRYSQ.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take and the vaccines you receive. Keep a list of the medications you take and the vaccines you receive to show your healthcare provider and pharmacist when you get a new medicine.

You may continue your daily injections while traveling. ZILBRYSQ may be stored at room temperature up to 86°F (30°C) in the original carton to protect it from light for a single period of up to 3 months.

After ZILBRYSQ prefilled syringes have been stored at room temperature, do not place them back in the refrigerator.

For more information about storing and taking ZILBRYSQ, visit the How to Use ZILBRYSQ page.

ONWARD is a personalized support experience built to help you through every step of your prescribed UCB treatment. With ONWARD, you’ll be paired with your own dedicated Care Coordinator* who will provide tailored support based on your unique needs.

For more information, please visit ucbONWARD.com.

*ONWARD Care Coordinators do not provide medical advice and will refer you to your healthcare professional for any questions related to your treatment plan. 
ONWARD is provided as a service of UCB and is intended to support the appropriate use of UCB medicines. ONWARD may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.

There are three ways to be enrolled in ONWARD:

• Ask your doctor to sign you up.

OR

• Download a Start Form and bring it to your doctor.

OR

• Call 1-844-ONWARD-1 (1-844-669-2731)1-844-ONWARD-1 (1-844-669-2731) Mon-Fri, 8:00 AM-8:00 PM ET.

Connect with others in the gMG community who may share your story. Check out these organizations and advocacy groups by visiting the below websites. This is not a complete list. Be sure to look for local support groups that may be in your area.

• https://myastheniagravis.org/
• https://myasthenia.org/
• http://www.mgakc.org/
• https://mgholisticsociety.org/

For more information, visit our gMG Community page.